Cypherpunk Technologies

Cypherpunk Technologies Financial Leverage

The Financial Leverage (Equity Multiplier) of Cypherpunk Technologies (CYPH) as of Oct 18, 2026 is 1.40. In the previous year, Financial Leverage (Equity Multiplier) was 1.21 — a change of 15.75% (higher).

Financial Leverage

1.40

YoY

15.75%

Last updated:

Financial Leverage (Equity Multiplier) of Cypherpunk Technologies is 2024 1.40 . Financial Leverage (Equity Multiplier) of Cypherpunk Technologies was 2023 1.21 . It decreases by 15.75% higher compared to the previous year.

The Cypherpunk Technologies Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2017
2.61 USD
Jan 1, 2018
2.08 USD
Jan 1, 2019
-4.26 USD
Jan 1, 2020
1.17 USD
Jan 1, 2021
1.09 USD
Jan 1, 2022
1.20 USD
Jan 1, 2023
1.21 USD
Jan 1, 2024
1.40 USD
The Cypherpunk Technologies Financial Leverage history
YEARFinancial LeverageYoY
1.40+15.75%
1.21+1.32%
1.20+9.35%
1.09-6.23%
1.17-127.37%
-4.26-304.84%
2.08-20.48%
2.61-1,302.44%
-0.22-23.94%
-0.29-11.33%
-0.32—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cypherpunk Technologies Stock analysis

What does Cypherpunk Technologies do? Cypherpunk Technologies Inc, trading under the ticker CYPH, is a biotechnology company based in Cambridge, United States. The company has a small workforce of six employees. It went public with an IPO on January 24, 2017. The company's website is https://www.leaptx.com/. The source description provided by the user contains unverified information, including the company's headquarters in Cambridge, Massachusetts, and details about its clinical stage programs, which are not confirmed by the facts provided. The source also mentions the company having 24 employees, which contradicts the provided employee count of six. Additionally, the source describes the company as developing monoclonal antibodies targeting cancer pathways, but these details are not part of the verified facts. The company's actual focus and product pipeline remain unconfirmed based on the information given. The source also incorrectly identifies the company as Leap Therapeutics, Inc., which is not the official name provided. The website provided, https://www.leaptx.com/, appears to be related to Leap Therapeutics, not Cypherpunk Technologies Inc. Therefore, the description is limited to the verified facts: the company's name, ticker, ISIN, country, city, sector, industry, employee count, IPO date, and website. No additional details about products, programs, or specific therapeutic targets can be included due to lack of verified information. Cypherpunk Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cypherpunk Technologies stock

Financial Leverage (Equity Multiplier) of Cypherpunk Technologies is 1.40 in 2024.

Financial Leverage (Equity Multiplier) of Cypherpunk Technologies changed from 1.21 to 1.40, representing a 15.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Cypherpunk Technologies since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Cypherpunk Technologies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Cypherpunk Technologies

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Cypherpunk Technologies